Advanced Phase IIa vulvodynia study with regulatory approval and patient enrollment, strengthened financial position through a SEK 48.3 million rights issue and convertible financing, and reported increased operating loss due to R&D and fundraising. Focus remains on clinical progress and partnering opportunities.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.